Revolution Medicines (RVMD) EBITDA (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly EBITDA of -$445.2 million for Q1 2026, down 84.92% year-over-year from -$3.0 billion in Q1 2025, and down 23.12% quarter-over-quarter from -$361.6 million in Q4 2025.
Revolution Medicines (RVMD) EBITDA (2019 - 2026) Analysis & Trends
Revolution Medicines' EBITDA history runs 8 years deep, the most recent figure standing at -$445.2 million for Q1 2026.
- In Q1 2026, EBITDA fell 84.92% year-over-year to -$445.2 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 75.68% YoY), while the FY2025 annual figure was -$1.2 billion, down 71.48% from the prior year.
- EBITDA for Q1 2026 stood at -$445.2 million, down from -$361.6 million in the prior quarter.
- The five-year high for EBITDA was -$57.9 million in Q1 2022, with the low at -$445.2 million in Q1 2026.
- The 5-year median for EBITDA is -$156.6 million (2024), against an average of -$180.2 million.
- The sharpest annual moves came in 2022 and 2023: EBITDA declined 16.62% in 2022, then tumbled 191.67% in 2023.
- Revolution Medicines' EBITDA stood at -$61.7 million in 2022, then sank by 191.67% to -$180.0 million in 2023, then slipped by 20.18% to -$216.3 million in 2024, then tumbled by 67.18% to -$361.6 million in 2025, then fell by 23.12% to -$445.2 million in 2026.
- Business Quant data shows RVMD's EBITDA at -$445.2 million in Q1 2026, -$361.6 million in Q4 2025, and -$315.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -505.13 Mn |
| Mar 31, 2026 | -445.22 Mn |
| Dec 31, 2025 | -361.63 Mn |
| Sep 30, 2025 | -315.27 Mn |
| Jun 30, 2025 | -264.71 Mn |
| Mar 31, 2025 | -240.76 Mn |
| Dec 31, 2024 | -216.31 Mn |
| Sep 30, 2024 | -175.71 Mn |
| Jun 30, 2024 | -156.64 Mn |
| Mar 31, 2024 | -140.86 Mn |
| Dec 31, 2023 | -179.98 Mn |
| Sep 30, 2023 | -123.25 Mn |
| Jun 30, 2023 | -108.80 Mn |
| Mar 31, 2023 | -75.16 Mn |
| Dec 31, 2022 | -61.71 Mn |
| Sep 30, 2022 | -76.53 Mn |
| Jun 30, 2022 | -62.09 Mn |
| Mar 31, 2022 | -57.95 Mn |
| Dec 31, 2021 | -52.91 Mn |
| Sep 30, 2021 | -53.16 Mn |